Tumor-driving IDH1 mutants catalyze a NADPH-dependent conversion of αKG to the oncometabolite D-2-hydroxyglutarate (D2HG), while typically ablating the conventional reaction1–3. This evidence concerns the gene IDH1 and neoplasm.